{"id":"W4386187511","doi":"10.1093/cid/ciad506","title":"Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes","year":2023,"lang":"en","type":"article","venue":"Clinical Infectious Diseases","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Houston Methodist Research Institute; Merck Sharp and Dohme; Genentech; National Institutes of Health; Norgine; Swedish Orphan Biovitrum; European Association for the Study of the Liver; Eisai; Sirtex Medical; Arrowhead Pharmaceuticals; University College London; Sysmex Corporation; Canadian Association for the Study of the Liver; Alnylam Pharmaceuticals; Vir Biotechnology; Silverback Therapeutics; Shionogi; Ipsen; Bundesinstitut für Arzneimittel und Medizinprodukte; Abbott Laboratories; Quest Diagnostics; Università degli Studi di Milano; Gilead Sciences; American Association for the Study of Liver Diseases; F. Hoffmann-La Roche; Alexion Pharmaceuticals; Roche; GlaxoSmithKline; Falk Foundation; Bristol-Myers Squibb","keywords":"Viewpoints; Medicine; Chronic hepatitis; Hepatitis B; Hepatitis B virus; Clinical trial; Family medicine; Intensive care medicine; Clinical research; Internal medicine; Virology; Virus","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.05772353,0.0004482699,0.001581703,0.0009698586,0.001342423,0.005239333,0.001381043,0.005054667,0.003966461],"category_scores_gemma":[0.09028207,0.000243834,0.002010912,0.001107779,0.005126358,0.006262393,0.001959389,0.00841686,0.0005992171],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00209847,"about_ca_system_score_gemma":0.003053807,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009002789,"about_ca_topic_score_gemma":0.001806158,"domain_scores_codex":[0.9567316,0.03079566,0.004070508,0.001859379,0.005822687,0.0007202676],"domain_scores_gemma":[0.8748872,0.09804291,0.007989397,0.006110568,0.009451146,0.003518645],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00203916,0.0002808319,0.007481936,0.006472754,0.0006066865,0.0009960779,0.001784283,0.0005980593,0.002253879,0.04551084,0.06672182,0.8652537],"study_design_scores_gemma":[0.0008417093,0.004278268,0.01111181,0.01268096,0.0008403578,0.00785178,0.002930458,0.0007392049,0.002784371,0.07615439,0.8795716,0.0002152139],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.01735116,0.4004865,0.009643427,0.546635,0.008965615,0.0002797066,0.0002201972,0.0001028926,0.01631547],"genre_scores_gemma":[0.1832924,0.2392804,0.02588098,0.498652,0.04373747,0.0008075651,0.0003371364,0.0002089155,0.007803137],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.05772353,"threshold_uncertainty_score":0.3052749,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05636783166306984,"score_gpt":0.3655714467191561,"score_spread":0.3092036150560863,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}